Last reviewed · How we verify
NCT03128164
A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
Phase 1 trial testing HMPL-689 in Lymphomas in 200 participants. Completed in 2 August 2023.
2 August 2023
Quick facts
| Lead sponsor | Hutchison Medipharma Limited |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 8 August 2017 |
| Primary completion | 2 August 2023 |
| Estimated completion | 2 August 2023 |
| Sites | 3 locations across China |
Drugs / interventions tested
- HMPL-689 — full drug profile →
Conditions studied
- Lymphomas — all drugs for Lymphomas →
Sponsor
Hutchison Medipharma Limited — full company profile →
Who can join
18 and older, any sex, with Lymphomas. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1, open-label study of HMPL-689 administered orally to patients with lymphoma for whom failed of standard care or have no standard of care.This study consists of a dose escalation stage (Stage I) and a dose expansion stage (Stage II).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03128164
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HMPL-689
Trials testing the same drug.
- NCT05713110 — A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma · Phase 2 · completed
- NCT04849351 — Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma · Phase 2 · completed
- NCT03786926 — Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas · Phase 1 · terminated
- NCT02631642 — A Study of HMPL-689 in Healthy Volunteers · Phase 1 · completed
Other recruiting trials for Lymphomas
Currently open trials in the same condition.
- NCT07002099 — Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible P · Phase 2 · recruiting
- NCT05773040 — A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or · Phase 1 · recruiting
- NCT00900198 — Collection of Tissue Samples for Cancer Research · recruiting
- NCT00006518 — Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cance · recruiting
Other Hutchison Medipharma Limited trials
Trials by the same sponsor.
- NCT05509699 — Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer · Phase 2 · completed
- NCT05318820 — A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manuf · EARLY_PHASE1 · completed
- NCT05277454 — Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT · Phase 1 · unknown
- NCT05015608 — Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification · Phase 3 · active not recruiting
- NCT05029635 — Phase III Study on HMPL-523 for Treatment of ITP · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03128164 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hutchison Medipharma Limited
- Last refreshed: 23 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03128164.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing